Clinical Trials Logo

Clinical Trial Summary

A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.


Clinical Trial Description

A Phase 2, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients with Moderate to Severe Atopic Dermatitis. The study is multi center and will consist of two dose levels:

Group A (n=9): patients will receive a total of 4 x 200mg subcutaneous injections of bermekimab. Dosing will occur weekly from visit 1 to visit 4, inclusive.

Group B (n=20): patients will receive a total of 8 x 400 mg subcutaneous injections of bermedimkb. Dosing will occur weekly from visit 1 to visit 8, inclusive. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03496974
Study type Interventional
Source XBiotech, Inc.
Contact Mark Williams, MD
Phone 737-207-4612
Email mwilliams@xbiotech.com
Status Recruiting
Phase Phase 2
Start date May 21, 2018
Completion date November 2018

See also
  Status Clinical Trial Phase
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Enrolling by invitation NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Not yet recruiting NCT03632174 - Evaluation and Comparison of 2 Cosmetic Investigational Products in Adults With Atopic Dermatitis N/A
Recruiting NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Recruiting NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2
Not yet recruiting NCT03684343 - Comparative Analysis of Filmed Sequences for the Assessment of Discomfort in Atopic Dermatitis of Infants Under 6 Months of Age N/A
Recruiting NCT02910791 - The Role of Bacterial Toxins in Human Skin Disease N/A
Recruiting NCT03051347 - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments N/A
Completed NCT02865356 - Topical Solution for the Treatment of Atopic Dermatitis Phase 2
Completed NCT02844452 - Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis N/A
Completed NCT02914548 - Study of OPA-15406 Ointment in Patients With Atopic Dermatitis Phase 2
Completed NCT02260986 - Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis Phase 3
Completed NCT01927705 - Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) Phase 1/Phase 2
Withdrawn NCT01936194 - The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis N/A
Recruiting NCT01692093 - KM110329 in Adult Patients With Atopic Dermatitis Phase 2
Terminated NCT01447758 - Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. Phase 1
Completed NCT01179880 - A Study of E6005 in Japanese Patients With Atopic Dermatitis Phase 1/Phase 2
Completed NCT01223222 - A Study to Evaluate Safety, Tolerability and Efficacy of Lytixarâ„¢ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection Phase 2